WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit sNDA for Pitolisant in Idiopathic Hypersomnia (IH) in Q4 2024 Based on Updated Strong and Sustained Efficacy Data from Long-Term Extension Study Next-Gen Pitolisant-GR and Pitolisant-HD Programs Advance; IND for Potential Best-In-Class, Novel Orexin-2 Agonist On Track for mid-2025, Extending Leadership in Sleep/Wake Beyond 2040s Highlights Most Advanced Development Program and Proven Serotonergic (5-HT 2 ) Mechanism of Action For EPX-100 in Rare Epilepsies; Pivotal Phase 3 Trial in Dravet Syndrome Ongoing; Phase 3 Registrational Trial in Lennox-Gastaut Syndrome to Initiate Before Year End Next Major Clinical Catalyst: Topline Data From ZYN-002 Pivotal Phase 3 RECONNECT Trial in Fragile X Syndrome on Track For mid-2025 Reiterates 2024 Net Product Revenue Guidance of $700 - $720 Million Conference Call and Webcast to be Held Today at 8:30 a.m.
ET PLYMOUTH MEETING, Pa. , Oct. 29, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc.
(Nasdaq: HRMY ), today reported a record $186.0 million in net revenue for the quarter ending on September 30, 2024 , surpassing $2 billion in cumulative net revenues since the launch of WAKIX ® in adult narcolepsy in November of 2019. In addition, the company recently hosted an Investor Day on October 1 , during which it highlighted its transformation into an innovative, catalyst-rich, self-fu.
